(Total Views: 379)
Posted On: 02/11/2019 11:01:34 AM
Post# of 72446
What will be the requirements for the expected topological creams of Brilacidin for dermatological uses?
I would expect some sort of tox study of the cream (on healthy patients?) to check out its physiokinetic properties, then a P2 (?) with a few different arms to get dosage down and see if efficacy meets goals, and then partner prior to P3?
Should the creams be that hard to formulate once IPIX gets going on them or are they pretty easy to create? Would formulating them most likely be outsourced?
If K pill is already about 1/2 done as to tox study, what time frame would seem likely to get the balance finished and get it approved to start testing on patients either in solo trials or complementary studies?
I would expect some sort of tox study of the cream (on healthy patients?) to check out its physiokinetic properties, then a P2 (?) with a few different arms to get dosage down and see if efficacy meets goals, and then partner prior to P3?
Should the creams be that hard to formulate once IPIX gets going on them or are they pretty easy to create? Would formulating them most likely be outsourced?
If K pill is already about 1/2 done as to tox study, what time frame would seem likely to get the balance finished and get it approved to start testing on patients either in solo trials or complementary studies?
(1)
(0)
